{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"8.8","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Overall survival will be displayed using Kaplan-Meier curves with median survival times and 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nInvestigational Agent: Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.\n\nSupportive Care Regimens: Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.\n\nNext Gen Sequencing Report: 1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.","id":"OG000","title":"Drug Administration Based on Next Gen Sequencing Report"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants, regardless of length of treatment.","reportingStatus":"POSTED","timeFrame":"From the start of treatment to date of death or date of last contact, up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}